Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index; none of the 73 sources its claims cite is checked for support yet.

The Pathomechanism and Current Treatments for Chronic Interstitial Cystitis and Bladder Pain Syndrome

Open access

Abstract

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic and debilitating condition characterized by symptoms such as bladder pain, frequent urination, and nocturia. Pain is typically perceived in the lower abdomen, pelvic floor, or urethra, causing significant discomfort and impacting quality of life. Due to the similarity of its symptoms with those of overactive bladder and acute bacterial cystitis, patients often face misdiagnosis and delayed appropriate treatment. Hunner’s (HIC) and non-Hunner’s IC (NHIC), each with distinct clinical presentations, urothelial dysfunction, chronic inflammation, and central sensitization and thus multimodal symptomatic treatment approaches, may be the most common pathogeneses of IC/BPS. Treatment of IC/BPS should involve identifying the different clinical phenotypes and underlying pathophysiology causing clinical symptoms and developing strategies tailored to the patient’s needs. This review discusses the roles of urine biomarkers, bladder inflammation, and glycosaminoglycans in the pathogenesis of IC/BPS. Various bladder treatment modalities are explored, including glycosaminoglycan replenishment, botulinum toxin A injection, platelet-rich plasma injection, low-energy shock waves, immunosuppression, and low-dose oral prednisolone. Pelvic floor muscle physiotherapy and bladder therapy combined with psychiatric consultation can help alleviate psychological stress and enhance the quality of life of patients with IC/BPS. Elucidating the pathological mechanisms and exploring diverse treatment options would help advance the care of individuals suffering from this challenging bladder condition.

Overview

CoChat Summary

TL;DR

IC/BPS is a chronic bladder pain syndrome with distinct Hunner (HIC) and non-Hunner (NHIC) phenotypes, each involving urothelial dysfunction, chronic inflammation, autoimmunity, viral infection, central sensitization, and pelvic/psychological factors. This narrative review synthesizes pathophysiologic mechanisms and proposes personalized multimodal therapy, including GAG replenishment, botulinum toxin A, platelet-rich plasma, low-energy shock waves, immunosuppression, and psychiatric/pelvic floor care.

Key findings

  • HIC and NHIC are distinct disorders: HIC features Hunner lesions, severe bladder pain, contracted bladder, dense inflammation, and lymphoid follicle aggregation in 40% of cases; NHIC features glomerulation after hydrodistension and more associated functional somatic syndromes. EBV was detected in 87.5% of HIC bladder tissues versus 17.4% of NHIC patients with high-grade glomerulation, with latent and lytic infection suggesting persistent/reactivated EBV.
  • Intravesical BoNT-A in a randomized placebo-controlled trial reduced pain at week 8 (−2.6 ± 2.8 vs. −0.9 ± 2.2, p = 0.021) and achieved success rates of 63% vs. 15% (p = 0.028); repeated injections were better than a single injection. PRP success improved from 45% after the first injection to 70% at the primary endpoint and remained 67.5% at 3 months after the fourth injection. LESW improved VAS ≥3 in 57.1% vs. 19.0% (LESWs vs. placebo; p = 0.011).
  • Other reported responses: antihistamines, 63% (38/60); intravesical tacrolimus, 56% (13/24); low-dose prednisolone in HIC, 64.5% at 12 months with mean maintenance dose 3.0 mg. Cyclosporine showed greater reduction in urinary frequency and higher subjective response than pentosan polysulfate; certolizumab pegol improved bladder pain and frequency but was not superior to placebo until 18 weeks; adalimumab was not superior to placebo.
  • The proposed multimodal algorithm is phenotype-driven: fulguration and antivirals for HIC; for NHIC, hydrodistension with BoNT-A every 6 months or suprapubic LESW plus GAG for significant pain/high-grade glomerulation; monthly PRP for four months plus GAG for frequency-predominant symptoms; pelvic floor physiotherapy and psychiatric consultation for pelvic pain and anxiety/depression.

Methods

  • Narrative review; literature searched in PubMed, MEDLINE, and ScienceDirect from 1982 to April 2024 using keywords “interstitial cystitis” or “bladder pain syndrome” or “painful bladder syndrome” and “pathophysiology” or “bladder therapy,” limited to English-language full-text articles.
  • Reviewed basic and clinical research on clinical characteristics, cystoscopic features, urine biomarkers, bladder inflammation, urothelial dysfunction, and novel bladder treatments; findings were synthesized narratively into a proposed multimodal treatment strategy. No systematic review, meta-analysis, or formal quality appraisal is described.

Limitations

  • Stated in the paper: data from large randomized controlled studies are limited for GAG replenishment; clinical trials for BoNT-A, PRP, and LESW are few; a randomized comparative trial is lacking; there has been no comparison of safety and efficacy between novel and conventional treatments; and treatment duration and biomarkers for determining antiviral treatment duration have not been established.
  • Evident from the text: this is a narrative review with a non-systematic search and no formal risk-of-bias assessment; many cited studies are small cohorts, single-center, or preliminary, and IC/BPS phenotypes are heterogeneous, limiting direct comparisons and generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/biomedicines12092051

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Electron microscopic (EM) examination of the ultrastructure of bladder urothelium in patients with (A) a normal urothelium (scanning EM), (B) non-Hunner’s interstitial cystitis (IC; scanning EM), and (C) Hunner’s IC (transmission EM).
Figure 1 Electron microscopic (EM) examination of the ultrastructure of bladder urothelium in patients with (A) a normal urothelium (scanning EM), (B) non-Hunner’s interstitial cystitis (IC; scanning EM), and (C) Hunner’s IC (transmission EM).CC BY · PubMed Central
Figure 2 Cystoscopic findings of interstitial cystitis/bladder pain syndrome under hydrodistension: (A) normal urothelium, no glomerulation; (B) grade 1 glomerulation; (C) grade 2 glomerulation; (D) grade 3 glomerulation; (E) Hunner’s lesion with urothelial crack; and (F) Hunner’s lesion with hemorrhagic patch. Magnification ×10.
Figure 2 Cystoscopic findings of interstitial cystitis/bladder pain syndrome under hydrodistension: (A) normal urothelium, no glomerulation; (B) grade 1 glomerulation; (C) grade 2 glomerulation; (D) grade 3 glomerulation; (E) Hunner’s lesion with urothelial crack; and (F) Hunner’s lesion with hemorrhagic patch. Magnification ×10.CC BY · PubMed Central
Figure 3 Multimodal therapy and strategy for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). Abbreviations: U/A: urinalysis, U/C: urine culture, Qmax: maximum flow rate, PVR: post-void residual, NSAID: non-steroidal anti-inflammatory agent, PFM: pelvic floor muscle, UDS: urodynamic study, VUDS: videourodynamic study, KCl: potassium chloride, BND: bladder neck dysfunction, DV: dysfunctional voiding, DO: detrusor overactivity, TUR: transurethral resection, CT: computed tomography, HIC: Hunner’s interstitial cystitis, MBC: maximum bladder capacity, Gr: grade, EBV: Epstein–Barr virus, LUTS: lower urinary tract symptoms, PFMT: pelvic floor muscle training, PTNS: percutaneous tibial nerve stimulation, TTNS: transcutaneous tibial nerve stimulation, SNS: sacral nerve stimulation, PRP: platelet-rich plasma, LESW: low-energy shock wave.
Figure 3 Multimodal therapy and strategy for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). Abbreviations: U/A: urinalysis, U/C: urine culture, Qmax: maximum flow rate, PVR: post-void residual, NSAID: non-steroidal anti-inflammatory agent, PFM: pelvic floor muscle, UDS: urodynamic study, VUDS: videourodynamic study, KCl: potassium chloride, BND: bladder neck dysfunction, DV: dysfunctional voiding, DO: detrusor overactivity, TUR: transurethral resection, CT: computed tomography, HIC: Hunner’s interstitial cystitis, MBC: maximum bladder capacity, Gr: grade, EBV: Epstein–Barr virus, LUTS: lower urinary tract symptoms, PFMT: pelvic floor muscle training, PTNS: percutaneous tibial nerve stimulation, TTNS: transcutaneous tibial nerve stimulation, SNS: sacral nerve stimulation, PRP: platelet-rich plasma, LESW: low-energy shock wave.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 1 Not valid · 62 Not checked · 10 Own results and interpretations

42 more claims

Create a free account to see all 73 claims and to verify the 73 references still open.

See all claims — free account
  • Probably not a substantial claim. 7
  • It may state two separate claims as one. 22

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Show all 99 references

Cited by

See all 39

Metadata

Authors
Yu, W.-R., Jhang, J.-F., Jiang, Y.-H., & Kuo, H.-C.
Affiliations
Tzu Chi University (TW)
Corresponding author
Kuo, Hann-Chorng
Venue
Biomedicines
Publisher
MDPI AG
Published
2024-09-10
Volume
12
Issue
9
Pages
2051
ISSN
2227-9059 (ISSN-L)
OpenAlex
W4402430374
Cited by
39
References
99
Citations by year
2026: 26 · 2025: 13
FWCI
3.13
Type
journal article
Language
en
Open access
Locations
  • Biomedicines (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Buddhist Tzu Chi Medical Foundation (TCMF-MP-110-03-01, TCMF-SP-112-01)
Topics
  • Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
  • Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
  • Health Sciences › Medicine › Urology › Urinary Tract Infections Management
Keywords
interstitial cystitis, urothelial dysfunction, chronic inflammation, central sensitization, urinary biomarkers, cystitis, glycosaminoglycans, botulinum toxin type A, platelet-rich plasma, low-energy shock wave therapy, immunosuppression, low-dose prednisolone, psychological stress, quality of life

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Pathomechanism and Current Treatments for Chronic Interstitial Cystitis and Bladder Pain Syndrome. https://app.cochat.ai/papers/10.3390/biomedicines12092051
The paper
Yu, W.-R., Jhang, J.-F., Jiang, Y.-H., & Kuo, H.-C. (2024). The Pathomechanism and Current Treatments for Chronic Interstitial Cystitis and Bladder Pain Syndrome. Biomedicines. https://doi.org/10.3390/biomedicines12092051

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.